Abstract
The adult myocardium responds to a variety of pathologic stimuli by hypertrophic growth that frequently progresses to heart failure. The calcium/calmodulin-dependent protein phosphatase calcineurin is a potent transducer of hypertrophic stimuli. Calcineurin dephosphorylates members of the nuclear factor of activated T cell (NFAT) family of transcription factors, which results in their translocation to the nucleus and activation of calcium-dependent genes. Glycogen synthase kinase-3 (GSK-3) phosphorylates NFAT proteins and antagonizes the actions of calcineurin by stimulating NFAT nuclear export. To determine whether activated GSK-3 can act as an antagonist of hypertrophic signaling in the adult heart in vivo , we generated transgenic mice that express a constitutively active form of GSK-3β under control of a cardiac-specific promoter. These mice were physiologically normal under nonstressed conditions, but their ability to mount a hypertrophic response to calcineurin activation was severely impaired. Similarly, cardiac-specific expression of activated GSK-3β diminished hypertrophy in response to chronic β-adrenergic stimulation and pressure overload. These findings reveal a role for GSK-3β as an inhibitor of hypertrophic signaling in the intact myocardium and suggest that elevation of cardiac GSK-3β activity may provide clinical benefit in the treatment of pathologic hypertrophy and heart failure.
References
47
Referenced
412
10.1146/annurev.genom.1.1.179
10.1016/S0092-8674(00)80043-4
10.1056/NEJM199005313222203
10.1038/81321
10.1172/JCI10079
10.1016/S0092-8674(00)81573-1
10.1073/pnas.051033698
10.1161/01.RES.87.9.731
10.1016/S0092-8674(00)80880-6
10.1074/jbc.275.12.8719
10.1073/pnas.97.3.1196
10.1016/S0092-8674(00)80571-1
10.1016/S0092-8674(00)81136-8
10.1126/science.275.5308.1930
10.1126/science.278.5343.1638
10.1038/35096075
10.1016/S0092-8674(01)00374-9
10.1038/378785a0
10.1006/dbio.2001.0317
10.1083/jcb.151.1.117
10.1074/jbc.275.19.14466
10.1161/01.CIR.103.5.670
10.1016/S0021-9258(18)31568-0
10.1161/01.CIR.101.24.2863
10.1042/bj3030701
10.1126/science.3260404
10.1126/science.8235597
10.1074/jbc.270.34.19898
10.1016/1074-7613(95)90027-6
10.1016/0092-8674(91)90241-P
10.1161/01.RES.83.4.345
10.1101/gad.11.8.957
10.1101/gad.12.22.3499
10.1073/pnas.83.21.8348
10.1161/01.RES.80.2.228
10.1128/MCB.20.14.5227-5234.2000
10.1161/hh2301.100003
10.1093/emboj/16.8.1888
10.1128/MCB.18.6.3518
10.1074/jbc.273.10.5423
10.1074/jbc.274.35.24858
10.1161/01.RES.86.3.255
10.1074/jbc.275.7.4693
10.1093/emboj/19.11.2537
10.1172/JCI119883
10.1073/pnas.051625598
10.1056/NEJM200007273430403
Dates
Type | When |
---|---|
Created | 23 years, 1 month ago (July 26, 2002, 10:36 a.m.) |
Deposited | 3 years, 4 months ago (April 13, 2022, 9:43 a.m.) |
Indexed | 1 week ago (Aug. 29, 2025, 6:25 a.m.) |
Issued | 23 years, 7 months ago (Jan. 8, 2002) |
Published | 23 years, 7 months ago (Jan. 8, 2002) |
Published Online | 23 years, 7 months ago (Jan. 8, 2002) |
Published Print | 23 years, 7 months ago (Jan. 22, 2002) |
@article{Antos_2002, title={Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo}, volume={99}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.231619298}, DOI={10.1073/pnas.231619298}, number={2}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Antos, Christopher L. and McKinsey, Timothy A. and Frey, Norbert and Kutschke, William and McAnally, John and Shelton, John M. and Richardson, James A. and Hill, Joseph A. and Olson, Eric N.}, year={2002}, month=jan, pages={907–912} }